TOKYO, April 29, 2025 /PRNewswire/ — The inaugural Taiwan-Japan Investment and Industry Networking Event took place at the Global Life Science Hub in Tokyo. The forum united leading biotech and pharmaceutical companies to explore cross-border investment, technology collaboration, and market growth. Key organizations—including BPIPO, DCB, LINK-J, and FIRM—highlighted partnership in regenerative medicine and drug innovation, aiming to bridge Taiwan’s biotech strengths with Japan’s investment and clinical development capabilities.
Strengthening Taiwan-Japan ties, seven pioneering biotech companies showcase innovation in regenerative medicine and drug development. Top: Dr. Hong-Lin Su, DuoGenic StemCells Chairman (right), signing a non-exclusive licensing agreement with Japan’s A&I Co., Ltd. Bottom: Pictured from left to right are Dr. Shuen-iu Hung, AngenMed Therapeutics CEO; Mr. Tang Shan Wen, GNT Chairman; Dr. Chih-Chuan Su, LumiSTAR Biotechnology Senior Business Development Manager; Ms. Fiona Tsai, BIONET Therapeutics Special Assistant to the General Manager; Dr. Sung Yuan Chen, HeXun Biosciences Vice General Manager; and Dr. Richard Shieh, Ascension Medical Biotechnology Chairman. Image: GeneOnline.
7 Taiwanese Companies Showcase Regenerative Medicine, Immuno-Oncology, and Precision Healthcare
Mr. Keita Komatsu, Deputy Director of the Bio-Industry Division at Japan’s Ministry of Economy, Trade and Industry (METI), expressed optimism for increased support in regenerative medicine investment programs between Taiwan and Japan. During the event, 6 leading Japanese venture capital firms and 30 pharmaceutical and biotech companies, including DCI Partners and Eight Roads Ventures, offered insights and emerging technologies.
Seven Taiwanese regenerative medicine companies were selected to showcase at the event, including:
DuoGenic StemCells Corporation highlighted its stem cell therapies for degenerative diseases. Chairman Hong-Lin Su noted, “Our 3-in-1 solution—platelet-rich fibrin, PBMCs, and growth factors—combines physical and chemical components to control osteoarthritis.” In a similar vein, Ascension Medical Biotechnology Co., Ltd. emphasized its integrated GMP manufacturing and clinical trial results. “We can induce over 100 types of exosomes, targeting a range of diseases,” Chairman Dr Richard Shieh explained.
For cancer care, AngenMed Therapeutics, Inc. presented its immuno-oncology therapies for solid tumors. CEO Shuen-iu Hung stated, “We enable precise anti-tumor immunity and long-term surveillance. Integrating clinical services and trials in Japan will accelerate our impact.”
Meanwhile, GNT Inc. showcased its nanotech and dermatology. Chairman Shan-Wen Tang said “GNT.Tec6, a needle-free, supersonic device for painless, non-invasive drug delivery also deliver exosomes hair follicle, promoting hair growth.”
Similarly, HeXun Biosciences Co., Ltd. offers full CDMO services from R&D to GMP production using automated systems. Vice GM Sung Yuan Chen said, “Automation boosts consistency and helps clients speed up development and ensure quality.
Furthermore, BIONET Therapeutics Corp. presented its AI-driven approach to cell therapies and exosome development. “AI streamlines data analysis and treatment optimization,” said Special Assistant Fiona Tsai. “We’re ready to take our exosome platform global.”
Finally, LumiSTAR Biotechnology, Inc. featured its iPSC Regenerative Medicine & Drug Screening Platform. Senior BD Manager Chih-Chuan Su remarked, “The tech may be complex, but the goal—faster drug discovery—is simple.”
Collectively, these companies highlight Taiwan’s vibrant biotech ecosystem, advancing global healthcare through regenerative medicine, oncology, diagnostics, and AI innovation.
DuoGenic StemCells and A&I Corporation Enter Licensing Agreement
A key highlight was the signing of a licensing agreement between Taiwan-based DuoGenic StemCells and Japan’s A&I Corporation, facilitated by BPIPO and FIRM. The deal grants A&I rights to DuoGenics’ AI Cells technology, therapeutic approvals, marketing, and sales in Japan, marking a milestone in Taiwan-Japan biotech collaboration.
The event not only opens new opportunities for biotech companies but also advances a robust biotech ecosystem rooted in cross-border collaboration.
